Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemic agents) on glycemic control, B-cell function and the remission rate in newly-diagnosed type 2 diabetic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborators: Guangdong Science and Technology Bureau, China; Hoffmann-La Roche; Ministry of Education, China; Novo Nordisk A/S
• Treatments: Gliclazide; Insulin; Insulin, Globin Zinc; Insulin, Isophane; Isophane insulin, beef; Isophane Insulin, Human; Metformin

Criteria

Inclusion Criteria:

1. informed consents be given before treatment

2. the newly-diagnosed type 2 diabetic patients

3. fasting blood glucose (FBG) level ranging from 7.0～16.7 mmol/L

4. age ranging from 25～70 years old

5. body mass index (BMI) ranging from20～35kg/m2

6. never be treated with any anti-hyperglycemic agents or anti-hyperlipidemic agents

Exclusion Criteria:

1. having any severe acute or chronic complications

2. renal dysfunction, blood creatinine≥150µmol/L

3. blood aminotransferase level rising up(more than 2 times of the normal level)

4. any severe cardiac disease including congestive cardiac failure, unstable angina and myocardial infarct in 12 months

5. serious hypertension (systolic pressure≥180mmHg and/ or diastolic pressure≥110mmHg)

6. chronic or acute pancreatic disease

7. severe systematic diseases or malignant tumor

8. allergic to the drugs using in the trial

9. any factors interfering the result

10. female patients incline to be pregnant

11. being treated with corticosteroid, immunosuppressing drugs or cytotoxic drugs

12. poor compliance